



## Embeda<sup>®</sup> (morphine/naltrexone) – Drug discontinuation

- On October 7, 2019 [Pfizer announced](#) the discontinuation of [Embeda \(morphine/naltrexone\)](#) extended-release capsules due to business reasons.
  - The discontinuation was not due to any safety, efficacy or quality issues.
  - Sales of Embeda will end on November 15, 2019 and the product is anticipated to be unavailable by early 2020.
- Embeda is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.